You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

LIPTRUZET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Liptruzet, and what generic alternatives are available?

Liptruzet is a drug marketed by Organon and is included in one NDA.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.

US Patents and Regulatory Information for LIPTRUZET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LIPTRUZET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ⤷  Try a Trial ⤷  Try a Trial
Organon LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LIPTRUZET

See the table below for patents covering LIPTRUZET around the world.

Country Patent Number Title Estimated Expiration
Mexico 9400281 FORMULACION DE CI-981 ORAL ESTABLE Y PROCESO PARA PREPARARLA. ⤷  Try a Trial
Slovenia 1148049 ⤷  Try a Trial
Canada 2220018 FORMES CRISTALLINES D'HEMI-SEL DE CALCIUM D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE(ATORVASTATINE) (CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN)) ⤷  Try a Trial
Israel 177377 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LIPTRUZET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 SPC014/2003 Ireland ⤷  Try a Trial SPC014/2003: 20050803, EXPIRES: 20171016
0720599 300688 Netherlands ⤷  Try a Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724
0720599 SPC001/2005 Ireland ⤷  Try a Trial SPC001/2005: 20050803, EXPIRES: 20190401
0720599 CR 2014 00050 Denmark ⤷  Try a Trial PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.